Dimensional Fund Advisors LP lifted its position in Simulations Plus, Inc. (NASDAQ:SLP) by 6.5% in the 2nd quarter, Holdings Channel reports. The firm owned 506,064 shares of the technology company’s stock after purchasing an additional 30,848 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Simulations Plus were worth $11,260,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently made changes to their positions in the company. Bank of Montreal Can acquired a new stake in Simulations Plus during the second quarter worth about $186,000. TIAA FSB acquired a new stake in Simulations Plus during the second quarter worth about $225,000. Acadian Asset Management LLC acquired a new stake in Simulations Plus during the second quarter worth about $233,000. Rhumbline Advisers acquired a new stake in Simulations Plus during the second quarter worth about $246,000. Finally, Citigroup Inc. grew its holdings in Simulations Plus by 1,154.8% during the first quarter. Citigroup Inc. now owns 11,670 shares of the technology company’s stock worth $172,000 after acquiring an additional 10,740 shares during the period. Hedge funds and other institutional investors own 35.70% of the company’s stock.
Shares of SLP opened at $20.57 on Friday. Simulations Plus, Inc. has a 12 month low of $14.25 and a 12 month high of $23.95. The company has a market capitalization of $350.77 million, a price-to-earnings ratio of 61.59 and a beta of -0.80.
Several research firms recently commented on SLP. BidaskClub raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research lowered Simulations Plus from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. Finally, ValuEngine lowered Simulations Plus from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 11th.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
See Also: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.